EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome

키워드

참고문헌 (39)

1. WHO Classification of Tumours Editorial Board, "Central nervous system tumours" (2021), International Agency for Research on Cancer
2. Broniscer A, "Supratentorial high-grade astrocytoma and diffuse brainstem glioma : two challenges for the pediatric oncologist", Oncologist, 9, pp.197~206 (2004)
3. Hadjipanayis CG, "Brain cancer propagating cells : biology, genetics and targeted therapies", Trends Mol Med, 15, pp.519~530 (2009)
4. Paugh BS, "Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease", J Clin Oncol, 28, pp.3061~3068 (2010)
5. Ohgaki H, "Epidemiology of brain tumors", Methods Mol Biol, 472, pp.323~342 (2009)
6. Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
7. Richter A, "EGFL7 mediates BMP9-induced sprouting angiogenesis of endothelial cells derived from human embryonic stem cells", Stem Cell Reports, 12, pp.1250~1259 (2019)
8. Parker LH, "The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation", Nature, 428, pp.754~758 (2004)
9. Fitch MJ, "Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells", Dev Dyn, 230, pp.316~324 (2004)
10. Hansen TF, "Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab", Sci Rep, 7, pp.2388~ (2017)
11. Shen X, "Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma", Biomed Pharmacother, 77, pp.167~175 (2016)
12. Huang CH, "Expression and clinical significance of EGFL7 in malignant glioma", J Cancer Res Clin Oncol, 136, pp.1737~1743 (2010)
13. Wang FY, "EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma", Cancer Lett, 384, pp.9~18 (2017)
14. Brunhara BB, "Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas", Neuropathology, 41, pp.21~28 (2021)
15. Fan C, "The expression of Egfl7 in human normal tissues and epithelial tumors", Int J Biol Markers, 28, pp.71~83 (2013)
16. Bidinotto LT, "Copy number profiling of Brazilian astrocytomas", G3(Bethesda), 6, pp.1867~1878 (2016)
17. Wan YW, "TCGA2STAT : simple TCGA data access for integrated statistical analysis in R", Bioinformatics, 32, pp.952~954 (2016)
18. Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
19. Huang da W, "Bioinformatics enrichment tools : paths toward the comprehensive functional analysis of large gene lists", Nucleic Acids Res, 37, pp.1~13 (2009)
20. Louis DN, "The 2021 WHO classification of tumors of the central nervous system : a summary", Neuro Oncol, 23, pp.1231~1251 (2021)
21. Cheng Z, "High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation", Cancer Biol Ther, 20, pp.1314~1318 (2019)
22. Papaioannou D, "Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia", Proc Natl Acad Sci U S A, 114, pp.E4641~7 (2017)
23. Yang C, "Increased expression of epidermal growth factor-like domain-containing protein 7 is predictive of poor prognosis in patients with hepatocellular carcinoma", J Cancer Res Ther, 14, pp.867~872 (2018)
24. 오진주, "High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer", Journal of Gynecologic Oncology, 25(4), pp.334~341 (2014), 대한부인종양학회
25. Li Z, "EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt", betacatenin signaling, 2018, pp.119, 10327~10337
26. Liu Q, "Role of EGFL7", EGFR-signaling pathway in migration and invasion of growth hormone-producing pituitary adenomas, 2018, pp.61, 893~901
27. Nichol D, "Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7", Blood, 116, pp.6133~6143 (2010)
28. Bill M, "EGFL7 antagonizes NOTCH signaling and represents a novel therapeutic target in acute myeloid leukemia", Clin Cancer Res, 26, pp.669~678 (2020)
29. Tang H, "EGFL7 silencing inactivates the Notch signaling pathway; enhancing cell apoptosis and suppressing cell proliferation in human cutaneous melanoma", Neoplasma, 66, pp.187~196 (2019)
30. Schmidt M, "The role of Egfl7 in vascular morphogenesis", Novartis Found Symp, 283, pp.18~28 (2007)
31. Hanahan D, "Hallmarks of cancer : the next generation", Cell, 144, pp.646~674 (2011)
32. Yeung S, "Abstract 3295 : inhibiting vascular morphogenesis in tumors : EGFL7 as a novel therapeutic target", Cancer Res, 71, pp.3295~ (2011)
33. Garcia-Carbonero R, "Randomized phase II trial of parsatuzumab(anti-EGFL7)or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer", Oncologist, 22, pp.375~ (2017)
34. von Pawel J, "Randomized phase II trial of parsatuzumab(anti-EGFL7)or placebo in combination with carboplatin, paclitaxel, and bevacizumab for first-line nonsquamous nonsmall cell lung cancer", Oncologist, 23, pp.654~ (2018)
35. Bicker F, "EGFL7 : a new player in homeostasis of the nervous system", Cell Cycle, 9, pp.1263~1269 (2010)
36. Shahcheraghi SH, "Wnt", beta-catenin and PI3K, mTOR signaling pathways in glioblastoma : two main targets for drug design : a review, pp.Curr Pharm Des, 2020[DOI]
37. Bos JL, "Rap1 signalling: adhering to new models", Nat Rev Mol Cell Biol, 2, pp.369~377 (2001)
38. Han J, "Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3", Curr Biol, 16, pp.1796~1806 (2006)
39. Sayyah J, "The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth", J Biol Chem, 289, pp.17689~17698 (2014)

관련 논문AI추천